| |
|
Dr. Robert K. Oldham
This
organization is under the guidance
of its CEO, Dr. Robert K. Oldham,
an internationally recognized
oncology/hematology specialist.
Dr. Oldham has realized his dream
of making advanced treatments
easily available to cancer patients
by establishing CTI, and the
related Clinical Services. He
is regarded as a leading pioneer
in the development and use of
Biotherapy - the fourth modality
in cancer treatment. Dr. Oldham
has been listed in "The
Best Doctors of America" since
Woodward / White began publishing
the list.
Dr. Oldham
attended the University of Missouri
at Columbia where his undergraduate
studies were in chemical engineering
and pre-medical sciences. He
completed his M.D. degree in
1968. During
medical school, he was awarded
a PHS Student Research Fellowship
and two PHS Cancer Clinical Research
Fellowships. Dr. Oldham
subsequently interned and did
his residency in Internal Medicine
at the Vanderbilt University
Hospital in Nashville. He
continued his education with
a Medical Oncology Fellowship
and graduate studies in immunology
at the National Cancer Institute
(NCI) in Bethesda, Maryland during
1970-1972. There he served
as Clinical Associate in the
Radiation Branch and in the Cellular
and Tumor Immunology Section
of the Laboratory of Cell Biology.
Research
and active leadership in cancer
treatment has been the ongoing
focus of Dr. Oldham’s
professional life. He
left the National Cancer Institute
in 1972 to serve as Research
Associate with Professor G. Mathe’ at
Hospital Paul Brousse in Villejuif,
France, then returned as Senior
Investigator in the National
Cancer Institute’s Cellular
and Tumor Immunology Section
of the Laboratory of Immunodiagnosis
during 1973-1975. From
1975-1980 he served as Associate
Professor of Medicine and Associate
Director of the Vanderbilt Cancer
Center where he also was Founder
and Director of the Division
of Oncology. Dr. Oldham
returned to the National Cancer
Institute from 1980-1984 to serve
as Associate Director of the
Division of Cancer Treatment
and as Founding Director of the
Biological Response Modifiers
Program. In 1984, Dr.
Oldham established the Biological
Therapy Institute (Founder and
Director) in Franklin, Tennessee;
the Biomedical Research Center
at the University of British
Columbia (Founder and Consultant);
and Biotherapeutics Incorporated
(Founder, Scientific Director
and Chairman of the Board) in
Nashville. Since then, he has
also served as Chairman of the
Board for Media America, Chairman
of the Board and President of
American Patient Services, Medical
Director of Cancer Treatment
Associates, and Chairman
of the Board and CEO of Cancer
Therapeutics Incorporated. In
addition to Dr. Oldham’s
current role with Cancer Therapeutics,
he is a Medical Oncologist with the New Mexico Cancer Center and holds a Clinical
Professorship of Medicine in
Hematology/Oncology at the
University of Missouri-Columbia
and is a Clinical Professor in
the Department of Biomedical
Sciences at Florida State University
College of Medicine. Dr.
Oldham currently serves as consulting
Medical Director and Vice President
for Business Development for
CBA Research in Lexington, Kentucky.
Dr. Oldham has received several
NCI clinical group appointments
including the Lung
Cancer and Southeastern Oncology
Study Groups. He was the
Founder and President of the
Society for Biological Therapy
and was Founder and Chairman
of the Cancer Biotherapy Study
Group. He has also acted
as consultant to various companies
in the US and abroad such as
Gen-Cell (Rhône-Poulenc),
Jenner Technologies, Wellcome
Biotechnology Ltd. and Amersham
Corporation in England. More
recently, he has been a senior
consultant with the American
Red Cross, Cell Genesys Inc.,
Xcyte Therapies and Maxim Pharmaceuticals. Dr.
Oldham is the founder and
has served as editor-in-chief
of three medical journals: Cancer
Biotherapy (now Cancer
Biotherapy & Radiopharmaceuticals), Molecular
Biotherapy, and Journal
of Biological Response Modifiers (now Journal
of Immunotherapy). He has
also served on the editorial
boards of three additional journals. He
is the editor of Principles
of Cancer Biotherapy - the
first comprehensive textbook
on the fourth modality of cancer
treatment and has authored or
edited thirteen books on cancer
treatment and research. Additionally,
he has contributed over 400 papers
to the medical/scientific literature
and has presented thousands of
abstracts, posters, and lectures
at various meetings on cancer
research and treatment. Dr.
Oldham has received many awards
and honors. He holds or has held
membership and/or office in 19
professional societies.
Click here for
Dr. Oldham's Curriculum
Vita in
Adobe Acrobat PDF format.
|
WALL STREET
JOURNAL EDITORIALS
Cracking the
FDA Code
A 21st Century
FDA
Our Bodies,
Our Cells?
Stem Cells:
Private Sector Can Do It Better
FDA Trials Cost
Lives
Unlucky Jim
PUBLICATIONS
and BOOK LIST
 |
The
Cure describes the lives of several
cancer patients as they attempt to
understand and deal with their devastating
disease. At the same time they read
of enormous opportunities in cancer
research and new treatments coming
to the forefront almost on a daily
basis, they encounter barriers and
difficulties in accessing new treatments.
They call about a promising new treatment
only to find that they are "not
eligible for the protocol."
They are about to begin a new form of therapy
when their insurance company tells them they
will not pay for the cutting edge treatment.
They talk to physicians involved in cancer
research and learn that many are on ego trips
for personal gain which actually slows progress
in the field, while others represent institutional
interests which lessen opportunities for the
patient.
It is through these trials and
tribulations that the cancer patients
in "The Cure" deal
with the problem of accessing new
treatments with a limited amount
of time and a critical illness.
Through the experiences of these
patients, the reader will come
to understand that cancer research
is a complicated human endeavor
where the patients' best interests
are not always at the forefront. |
 |
"BioEthics" is
a compilation of writings by Dr.
Robert K. Oldham, a prominent oncologist
with experience at the National Cancer
Institute, the university and in
the private sector, as well as the
writings of other individuals concerned
with the ethics of cancer research.
"BioEthics" allows
the reader to better understand
the complexities of drug development,
insurance reimbursement, federal
regulations, and the inner workings
of the cancer research and treatment
establishment. Although many believe
these entities are working for
the cancer patient, it is clear
from the writings contained within
this book, that sometimes conflicts
develop which actually impede the
progress of physicians attempting
to bring new treatments forward
for patients with cancer.
"BioEthics" represents
an excellent reference work for all
those involved in the field of cancer
research, cancer treatment, bioethics,
and medicine. In addition, it allows
the patient reader to better understand
the difficulties of accessing new
treatment in the United States |
 |
Cancer
Biotherapy and Radiopharmaceuticals
is a bi-monthly journal which reports
new and innovative investigations
of methods to improve cancer therapy.
This includes more selective delivery
of drugs, biologicals and radiopharmaceuticals,
as well as advances in delivery instrumentation
and technology, with the aim to increase
the efficacy of therapy and/or decrease
toxicity, and improve the convenience
of therapy.
Link
to publisher's site |
 |
"Principles
of Cancer Biotherapy", now available
in the 4th Edition, contains
the latest information in the biological
therapy of cancer, the fourth modality
of cancer treatment. Most of the
exciting new advances in cancer treatment
are occurring in the field of biological
therapy, which complements the older
modalities of surgery, radiation
therapy and chemotherapy. "Principles
of Cancer Biotherapy" is written
in a user-friendly style and is an
invaluable resource for clinical
oncologists/ hematologists, nurses,
physicians
and medical students.
Link to introduction
Link
to publisher's site
Click
here for brochure in Adobe Acrobat
PDF format
|
 |
In
"The Resurrection", the bridge
between life and death is
discovered by a world-renowned
neurosurgeon – but
it just might cost him his life in
this taut, well-paced medical thriller.
Dreams are the substance of the soul – and
when Dr. Robert Gordon discovers
their chemical and spiritual link
to the afterlife, bitter medical
rivals and a host of rogue government
agents will stop at nothing to
steal the good doctor's research – even
if it means murdering him in order
to claim the prize for themselves.
The bridge between life and death
might be Dr. Gordon's only hope
to save his own life.
In the tradition
of Robin Cook and Michael Crichton,
this razor-edged
thriller takes the reader
on a nerve-jangling journey to
life beyond time and the grave – with
enough unexpected twists and turns
to keep scientists and theologians
scratching their heads and wondering, “Why
didn't I think of that?”
“A
classic battle of good versus evil
at the last frontier: Death and
the Afterlife.”
— Dr.
J. Steven Johnson, Radiation Oncologist,
John D. Archbold Memorial Hospital.
“What a great
read … I found it so provocative
and interesting I couldn’t
put it down once I started it.”
— Dr. Gerald
N. Kadis, Neurosurgeon, South Georgia
Neurological Institute.
“The
Resurrection was a fast-paced,
engaging, fun medical mystery that
wove in insights about clinical
research and the FDA, based on
Dr. Oldham’s
distinguished career as a cutting-edge
researcher.”
— Lynn
S. Bachrach, president and CEO,
Clinical Research Group, Inc.
Link to publisher's site |
Please leave e-mail regarding questions for Dr. Oldham, subscription
to Cancer Biotherapy and Radiopharmaceuticals,
or the purchasing of any of Dr. Oldham's
books.
For
more information on Dr. Oldham's books
please visit www.droldham.com.
|
